Excellent post and article fouremm, thanks. Reminds me of Segal at SNIPRx. Great example of successful leadership… i.e. winning, not just keeping the ship afloat.

This article is a must read for all RVX and ZCC shareholders…read it an weep because it gives the clearest picture to explain mushroom management vs. leadership management.

Trillium Therapeutics market cap at start was $16 million…2 years a later $2.26 billion buyout by Pfizer.

The case illustrates the need for a full team of scientists, business experts with financing and relationship building skills and a large enough and diverse enough board of directors. Trust and transparency are emphasized as key success drivers.

A Brief Bullet Point Summary

Products - CD47 inhibitors – TTI-622 and TTI-621

• Targets – multiple cancer indications
• Team – 50 expert drug developers

Skvarka Background

MBA

Bain Consulting

Current - Chairman DEM Biopharma, board member of Zentalis and Monte Rosa Therapeutics

His Actions at Trillium

• Created six indication specific Key Opinion Leader panels
• Moved head quarters to Cambridge, Mass
• Raised $300 million in 2 financings
• Secured $25 million equity deal with Pfizer
• Brought the Pfizer CSO of oncology on to the scientific advisory board
• At start of Covid bought 2 years of manufacturing capacity in advance
• Increased trial enrollment despite Covid and completed phase 1 studies
• Held over 400 investor meetings in 2020
• Recruited high profile board members
• Apr 2021 – launched nine clinical phase 2 studies

Skvarka

1. “It is critical to have a vision and be crystal clear about the company’s direction”.
2. Key to success – “Don’t oversell, always be honest”
3. Keys to success with Pfizer – Skvarka – “Trust is key”.

Skvarka then discusses the importance of the team.

Must be read in fully to appreciate.

Happy Thanksgiving to our American partners and friends. I’ve got the Dallas vs Washington on.

GLTA

Toinv